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Abstract
Sickle cell disease (SCD) is a structural and monogenetic genetic disorder due to a muta-
tion that occurs in the globin β-chain, resulting in the formation of hemoglobin S (Hb S), a
protein composed of two normal, and two β-type mutant chains. Estimates indicate that
the prevalence among live births is 4.4% in the world. The difficulty in circulating the
sickle cell, its interaction with endothelial cells, leukocytes, platelets, endothelial dysfunc-
tion, and the abnormal expression of adhesion molecules permeate the beginning of the
blood vessel occlusion process as well as pathophysiological aspects of SCD. Among the
secondary complications are the stroke, pulmonary hypertension, leg ulcer, renal disor-
ders, and all complications associated with vascular dysfunction. Clinical and biochemical
markers of disease severity can be used to predict risk, prevent complications, and
increase the expectation and quality of life of the SCD population. The entire scenario
generated by Hb S has implications for the health and social inclusion of patients, so the
treatment of the person with SCD needs an approach focused on the prevention of these
complications in an individualized way.
Keywords: sickle cell disease (SCD), hemoglobin, genetic disturber, nucleation, molecular
interaction
1. Introduction
According to global estimates, approximately 5% of the population has some type of hemo-
globin variant, and more than 300,000 babies are born each year with hemoglobinopathies,
with sickle cell disease (SCD) being the most prevalent type [1–2]. It is estimated that the
prevalence of live births with the disease is 4.4% in the world, where rates remain high on the
main continents of Africa, Southeast Asia, and the Americas [2].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In 2013, perform a first evidence analysis focusing on sickle hemoglobin using a 2010 dataset
combined with demographic data and modern geostatistical modeling techniques that explain
spatial heterogeneities and precision measurements of global statistics about sickle cell disease
neonates (Figure 1) [3]. In 2010, the births of infants with sickle cell anemia (SCA-Hb SS)
accounted for 2.4% of the world's most severe cases of the disease [3]. However, worrying
estimates indicate that the number of newborns with SCA will increase from approximately
305,000 in 2010 to 404,000 in 2050 [4, 5].
The African continent, which has 3.6 million new cases of sickle cell trait (HbAS) and 238,000
SCA, remains the largest cradle of SCD genetic inheritance [3]. Nigeria, and the Democratic
Republic of Congo would urgently need to plan policies for prevention and management of
SCA, so that implementations carried out in 2015 could save many lives by 2050 (Figure 2) [4, 5].
In Southeast Asia where a hemoglobin variant Hb E is more prevalent, a heterozygosity with
Hb S has increased mainly due to immigration and interracial relationships [6–8]. Neverthe-
less, according to data between the years 1990 and 2013, an annual mortality rate SCD HbSE
per 100,000 inhabitants decreased by 63.9%, keeping them in the media of 2.8% per year [9]. It
is estimated that the prevalence of live births with the SCD is 1.1% in the American continent
[2]. In the United States, it is estimated that 113,000 hospitalizations are in the occurrence of the
disease and the cost of hospitalization for SCD reaches 488 million dollars per year [10].
In Brazil, the estimated incidence of SCD is 1 case per 2700 live births: Bahia, Rio de Janeiro,
and Minas Gerais being the main states with the highest prevalence [11–13]. According to data
from the Ministry of Health of Brazil, child and perinatal care lethality rates can reach 80% and
between 20% and 50%, respectively, of uncared children who cannot reach 5 years of life [14].
Among the adults followed in the high prevalence states, such as Bahia and Rio de Janeiro, the
median age of death due to SCD is still low, 26.5 years and 31.5 years, respectively [15].
Nevertheless, in the last 13 years, the Brazilian government implemented several public health
policies focused on the detection of new cases by neonatal screening and on improving the
quality of treatment provided to these patients, implying an increase in life expectancy, with
individuals reaching the fourth, fifth, and up to the sixth decade of life [16–19].
Figure 1. Distributions HbS data points. Red points indicate surveys showing the presence of HbS and blue points
indicate surveys showing an absence of HbS. Source: Adaptation of Piels et al. [3].
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The pathological presentment of SCD begins with the process of formation of Hb S polymers
triggers dehydration and increased cell stiffness, giving rise to the vaso-occlusion event [20, 21].
This phenomenon leads to the appearance of several pathophysiological events such as tissue
ischemia, anemia, inflammation, and hemolysis [20–24].
Hemolysis consists of the early destruction of the erythrocytes by membrane rupture, being a
common event in the pathophysiological process of SCD [25–27]. During hemolysis, vasodila-
tion, transcriptional activation of endothelin and vascular adhesion molecule are reduced,
whereas nitric oxide is exposed directly to free Hb S, causing its degradation [28, 29]. Chronic
hemolysis in SCD causes vascular imbalance, reflecting directly on hemoglobin concentration,
reticulocyte count, bilirubin levels, lactic dehydrogenase (LDH), and nitric oxide bioavailabil-
ity [28, 30, 31]. The reduction of the supply of oxygen to the tissues and organs causes the
appearance of several complications secondary to disease [5].
Nevertheless, genetic, age, gender, hematological, and environmental factors afford to inter-
fere on the characteristics of SCD and also impact on the quality and life expectancy of
patients, mainly reducing their social insertion [32–35].
2. The hemoglobin: origins and function
Hemoglobin is one of the most abundant proteins in animals, performing important functions
such as oxygen transport, started when hemoglobin binds to oxygen that arrives from the
airways in the lungs and is taken to organs and tissues that need it to maintain life through red
blood cells [36–38]. The genomic structure of genes encoding hemoglobin subunits, character-
ized by three exons and two introns, are highly similar among vertebrate animal strains [39].
Figure 2. Numbers of Newborns with Sickle Cell Anemia (SCA) in 2015. Source: Adaptation of Piels et al., 2017.
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Despite this, the function of some proteins belonging to the contemporary hemoglobin family
in vertebrates is to store oxygen in tissues such as myoglobin, a protein formed by a globin
chain, gives the red color to the muscular tissues and has structural and genomes similar to
globins that form hemoglobin [37, 40–43].
Composed of four polypeptide subunits, two alpha chains and two beta chains (α1β1; α2β2),
respectively, each of the four globin groups has a porphyrin ring (Heme group) containing the
iron element in its constitution (Figure 3) [38, 44].
Hemoglobin is considered an allosteric molecule because it regulates its functionality very
well, especially in situations of change in the environment where it is present, in the increase
or decrease of the concentration of a certain ligand [45, 46]. A classic example of this can be
highlighted in how oxygen binds cooperatively in the heme cluster [47, 48].
Previously, researchers admitted that the base of hemoglobin allosterism was based on the
Monod Wyman-Changeux (MWC) two-state allosteric model, which corresponded to oxyhe-
moglobin (bound) and deoxyhemoglobin (unlinked) forms [44, 46, 49]. It is currently believed
that hemoglobin can adopt several allosteric conformations in dynamic equilibrium, also
implying different functionalities (Figure 4) [44, 48].
Over time hemoglobin has been consistently an object of scientific research given its relevance
to biology [50–52]. One of the most important aspects is related to the study of its origin and its
relation with oxygen, a very reactive metal, but necessary for mammalian metabolism [53–55].
Figure 3. Structure quaternary of hemoglobin. Source: Antranik website: Available in http://antranik.org/blood-components-
hemoglobin-typerh-factor-agglutination.
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From the evolutionary point of view, about 4 billion years ago, the gaseous layer that
enveloped the Earth was composed only of nitrogen, methane, water effluvia, and ammonia
[37]. Probably many organisms that emerged in the early days used these gases for their own
subsistence [56]. It is believed that iron and magnesium were involved in many of these actions
in the metabolism of these extremely primitive organisms [57, 58].
In order to increase the efficiency of life-generating energy systems, somehow still not so
enlightened and despite being toxic, oxygen has been incorporated by organisms [37, 50]. It is
believed that initially this large protein complex that now bears oxygen-dependent organisms,
organs, and tissues was very primitive, probably composed only of a metal that was able to
bind and carry oxygen [37].
In the process of evolution, at one point, it was necessary that this structure is wrapped within
a porphyrin ring and then embedded in enovelled protein [52]. During evolution, this ring-
shaped structure has accompanied generations of organisms of animal origin (Heme group)
and plant (Clorofila group) [37, 59].
The Heme group not only binds to globin molecules to form hemoglobin but can bind other
molecules with a certain function to give rise to oxygenases proteins, cytochromes, and even
fungal ligninases [37]. Chlorophyll, the green-coloured substance in plants, is basically an
organic molecule characterized by a porphyrin ring that contains magnesium, and its function
is to absorb electromagnetic energy through sunlight, which will be used in photosynthesis
[58, 60, 61].
Studies to identify the origin of hemoglobin compare their respective coding genes with
several parent organisms in order to detect the changes that have been made throughout
evolutionary history and time [37]. But the change identified in hemoglobins was more in the
form of how they are genetically regulated than in their structural basis from which they were
strongly conserved [58]. In general, studies indicate that hemoglobin appeared about 500
million years ago (Figure 5), prior to the time that eukaryotic cells diverged from eubacterial
cells [37].
Figure 4. Presentation and comparison of nine quaternary structures of hemoglobin. In (a) diagram showing the orienta-
tion of α2β2 dimers relative to α1β1. In (b) the presentation of the β2 subunit with the same nine conformations
represented in nine colors and at different angles. Source: Adapted from Shibayama et al. [44].
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3. Pathophysiology of Hb S: a mutation, an amino acid, a disease
Multipotent hematopoietic stem cells have the potential to be targeted to a number of special
differentiation pathways that originate several blood cell lines in mammals [62–64]. One of the
pathways, erythropoiesis, is responsible for the production of red blood cells, discoid and
anucleated cells that carry oxygen (O2) and carbon dioxide (CO2) through an intracellular
metalloprotein called hemoglobin throughout the body [39, 65].
As seen previously, hemoglobin is a heterotetramer composed of two α-globin and β-globin
subunits linked by a non-covalent bond [2, 39]. Each globin subunit has a heme group contai-
ning the bivalent iron ion [64, 66].
Different globin genes are activated or deactivated both in embryonic, fetal and adult life in
order to meet different oxygen demands and facilitate the placental transfer of oxygen from
the mother to the embryo (Figures 6 and 7) [64, 66, 67].
In humans, throughout embryonic life to adulthood, various types of hemoglobin can be
expressed and this process is regulated in a complex manner, involving several molecular
mediators in order to stimulate hemoglobin production (Figure 6) [2, 66, 68 ]. The globin genes
α and β, arranged on chromosomes 16 and 11, respectively, control the production of globins
through the expression of the subunits from the α globin locus: ζ (embryonic) and α-globin
(adult) genes; and locus β globin: ε (embryonic), γG and γA (fetal), and δ and β-globin (adult)
(Figure 7) [64, 66].
However, due to spontaneous mutations, variant hemoglobins may arise and be structurally
different [68, 69]. These mutations can, for example, trigger a change in the amino acid sequence,
Figure 5. Phylogenetic tree model of globin genes in vertebrate animals. Source: Adapted from Hardison [58].
Thalassemia and Other Hemolytic Anemias94
Figure 6. Representation of the red cell maturation process, molecular regulation of hemoglobin (embryonic, fetal, and
adult) with focus on β globin and globin synthesis. Source: For more details, look up the Sankaran article reference of the
year 2011 [68].
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leading to the decrease or suppression of the production of a globin chain, as observed in β
Thalassemia [70, 71]. Such genetic changes often lead to the onset of diseases, which are called
hemoglobinopathies [2, 8, 72].
A mutation in the gene of the sixth codon of exon 1 in the DNA of chromosome 11, which
synthesizes the β globin, leads to the replaced adenine nitrogen base (from the GAG codon) by
thymine (GTG), resulting in the substitution of glutamic acid for valine in position 6 of the N-
terminal end in the Beta (β) chain of globin [73–76] .The pathophysiology of sickle cell disease
(SCD), a monogenetic disorder that gives rise to the formation of hemoglobin S (Hb S), a
protein composed of two normal α-chains and two mutant chains of the β-type (α2A β2S)
(Figure 8).
Three levels direct the scientific knowledge related to the pathophysiological changes present
in SCD: molecular and cellular, tissue and organism [77–80]. At the molecular level, the
exchange of amino acids with different isoelectric points, glutamic acid (IP = 5.97) per valine
(IP = 2.77), causes an imbalance because of the loss of negative charges of Hb S in relation to Hb
A (Figure 9) [81, 82]. These changes in the physical structure of hemoglobin will imply impair-
ments in its functionality, mainly related to oxygen loading [83–85].
In certain periods or situations where hypoxia occurs (absence or decrease of oxygen tension in
the body), oxygenated mutant hemoglobin (oxy-HbS) loses oxygen, adopting deoxygenated
conformation (deoxy-Hb S) [81, 86, 87].
Figure 7. Variation of hemoglobin types in the embryonic, fetal, and adult period. Source: Adapted from Weatherall and
Clegg [113].
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In its own structure, the formation of hydrogen bonds between the amino acids valine of
position n1 of the globin beta S (normal position) and the mutant valine of the same globin
begins [82, 83, 84]. Hydrogen bridges promote intermolecular approximations and contacts
between the amino acids of hemoglobins (GLU121! GLY16, ASP73! THR4, etc.) that favor
the formation of Hb S polymers [84, 85]. However, it is through the hydrophobic interactions
between valine (βVAL6) and the hydrophobic concavity formed mainly by leucine (βLEU88)
and phenylalanine (βFEN85) that the formation of Hb S polymers occurs [81, 83, 88].
Figure 9. Representation of the mutated amino acid structures present in HbS. Glutamic acid has an acted structure and
with more negative charges. Valine is an amino acid with hydrophobic characteristics that tend to have the most neutral
charge. Source: Wishart et al., 2013.
Figure 8. Crystalline structure of deoxy hemoglobin S (deoxy-Hb S). Source: For more information, see details in the
study by Harrington et al., 2017.
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Figure 10. Summary of the pathophysiology of SCD. (A) Representation of the structural differences in the conformation
of HbS when it is in oxygenated and deoxygenated form. (B) HbS polymerization process with details of the main amino
acids involved in the mechanism. (C) Formation of the deoxy-HbS fibers through the phenomenon of homogeneous and
heterogeneous nucleation. (D) Microscopic findings of sickle cell. Left cells of the blood with the formation of Heinz
bodies (fluorescence method). In the center, smear blade containing scythe-shaped cells. On the right is a lysed sickle cell
showing several deoxy-HbS fibers. Source: See details at Howard Hughes Medical Institute, 2018; Galkin et al. [88];
Rooter, 2005; Liu et al., 1996.
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Polymerization in SCD is a process triggered by a phenomenon known as nucleation in which
a number of molecules come together within an embryo of the new phase that resembles a first
transition phase similar to a gas-solid transformation [88, 89]. The nucleation progressively
progresses through the initial fiber growth and its branching, due to the secondary nucleation
of new fibers on top of the existing ones, as if it were a double nucleation [77, 88, 90, 91].
Polymerization of HbS is a primary event in the pathophysiology of SCD, generally favored by
several factors such as insufficient oxygen saturation, loss of potassium and water, reductions
in blood pH, increased the concentration of 2, 3-diphosphoglycerate [81, 82, 86]. In the forma-
tion of HbS fibers, they are capable of generating 14 members of T-shaped conformation fibers
when hemoglobin is in the deoxygenated state [87, 88]. Among these aligned fibers hydropho-
bic contacts occur, which are initiated between the valine of the HbS molecule and alanine,
phenylalanine and leucine of adjacent Hb S molecules [88]. In the case of a high degree of
polymerization, the deoxy-HbS presents a behavior characteristic of a polymer gel [88, 90].
After polymerization progresses through enveloped fibers, which will alter the structure of the
red cell, mainly through the formation of more elongated fibers and mechanisms of precipita-
tion in the cell wall with the formation of Heinz bodies, triggering the appearance of sickle-
shaped red blood cells, rather than discoid and malleable (Figure 10) [81, 82, 87].
The affinity of oxygen for hemoglobin, Hb S concentration, dehydration, the minimum con-
centration of gelation, acidosis and elevated temperature are determinant events, which
directly influence the falcization process [92].
Sickle cells have a rigid, adherent and fragile structure, which compromises their circulation in
the bloodstream [86, 87]. Cell damage and deformation of erythrocytes occur as a result of
polymerization of deoxy-HbS and high concentrations of unpolymerized oxy-HbS, as well as
influenced by cellular levels of HbF, water content, pH, temperature and mechanical stresses
that will result in membrane injury [84].
The difficulty of circulating the sickle cell, its interaction with endothelial cells, leukocytes,
platelets, endothelial dysfunction and the abnormal expression of adhesion molecules perme-
ate the beginning of the process of occlusion of the blood vessels, generating tissue hypoxia,
hemolysis, increased oxidative stress and other pro-inflammatory phenomena [80, 87, 91, 93].
4. Clinical consequences of the presence of Hb S
SCD is a chronic hemolytic anemia characterized by clinical events involving recurrent vaso-
occlusion, and its main clinical manifestations are anemia, pain, and multiple organ failures
[18, 80, 87]. To understand the clinical aspects of SCD, we must go a bit further into the
pathophysiological and molecular aspects of this genetic disorder.
As we saw earlier, the presence of a genetic alteration in the nitrogen base in the gene that
encodes the β globin production triggers the formation of HbS, modifies the structure of the
erythrocytes (Figure 11), and implies a series of pathophysiological complications for individuals
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with SCD. Many of the following events do not occur in isolation and are directly involved in the
pathogenesis of SCD.
The sickle cell has many difficulties in permeating the blood vessels. Due to the speed of the
bloodstream, many end up clinging to each other thus harming the passage. Sickle cell occlu-
sion mechanism is started. Spleen cells are pounded, violently pushed, lysed, and intravascu-
lar hemolysis causes the red blood cells to release a series of biocomponents, mainly
hemoglobin and arginase that will interact with nitric oxide (NO) produced in the endothe-
lium, reducing its bioavailability and arginine and its main precursor [84, 94, 95].
The vessel occlusion plus constant hemolysis initiates tissue hypoxia. At the same time, early
oxidation of NO increases oxidative stress implying endothelial dysfunction, with imbalances
in the mechanisms of vessel dilatation and constriction [84, 85].
At a time when local occlusion ends, and blood perfusion returns, more free radicals are
produced, and they further increase lesions to the endothelium, which becomes more adher-
ent, especially to red blood cells and leukocytes, making the vascular wall again exposed to a
new occlusion [84, 95, 96].
Among the main adhesion pathways that progress the sickle cell and endothelial cell interac-
tions are the soluble adhesion proteins (thrombospondin, fibrinogen, fibronectin, and von
Willebrand factor), integrins (α4β1, αVβ3) and their membrane-bound receptors and sulfated
glycolipids), immunoglobulins VCAM-1 and ICAM-4, endothelial selectin, as well as leuko-
cyte activation by epinephrine through β-AR stimulation [85, 96].
Recurrent hemolysis eventually becomes chronic, and the inflammatory state is established.
Thus, the organism needs to increase the production of red blood cells by the bone marrow,
Figure 11. Microscopic finding showing structural differences observed in normal form (oxy-HbS) and sickle cell (Deoxy-
HbS), responsible for the pathological aspects in individuals with SCD. Source: Site of Howard Hughes Medical Institute,
2018.
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resulting in high cardiovascular work, with increased cardiac output in order to facilitate the
rapid delivery of blood with a higher content of oxygen to the organs, avoiding hypoxia and
tissue death [97]. More precisely, a compensatory mechanism is established that increases heart
rate, leading to increased myocardial energy demand with the effect between myocardial
energy requirements and total body [98, 99, 100].
The hypermetabolism present in these patients has an impact on body composition and has
been related to increased energy expenditure, increased protein turnover, increased oxidative
stress, higher reticulocyte levels, and reduced body mass [97, 99, 101, 102].
Progressive degeneration of the organs results from infarctions in the affected areas, leading to
several secondary complications that directly compromise patients' lives and survival [18, 80, 103].
Patients with SCD are more likely to have episodes of vascular accident, pulmonary hyperten-
sion, proteinuria and chronic kidney disease, all complications associated with vascular dys-
function caused by the disease [78, 94, 104, 105].
Vasodilation is reduced in patients with SCD and may have other consequences, such as the
appearance of leg ulcers [94, 106, 107]. These lower limb ulcer lesions represent 8 to 10% of the
cases and have a higher incidence in people with SCA males and in the age group between 10
and 50 years [99, 107, 108, 109].
Ulcerations may appear after trauma, insect bites, excessive dryness of the skin or spontane-
ously generally in the ankle or malleolar region (middle or lateral portion), where there are less
subcutaneous tissue and blood flow as a consequence of tissue hypoxia, endothelial dysfunc-
tion, and vaso-occlusion [107, 108, 110].
Figure 12. Major complications secondary to SCD. Source: The illustration has been adapted from the Toda Matéria
website. For more details, refer to the articles Ballas et al. [78]; Saraf et al. [104]; Saraf et al., [105]; Gordbach et al., 2012;
Piels et al., 2017; Di nuzzo & Fonseca [76]; Machado, 2007; Gumiero et al., 2007; Brunetta et al., 2010; Paladino, 2007;
Hyacinth et al. [99]; Marques et al., 2012; Cançado, 2007; Lobo et al., 2010; Borsato et al., 2000; Saad eTraina, 2007,
Marques et al., 2012; Caridade et al., 2007.
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Infections in these patients are also a major cause of concern both in childhood and in adult-
hood [76, 78, 111, 112]. In general, this and other complications (Figure 12) bring many mis-
fortunes to individuals with SCD and basically compromise the quality of life of these patients.
Despite all the consequences of HbS formation, the degree of severity of the disease depends
on numerous factors, and the first one is the genotype.
SCD can be subdivided into distinct genotypes, six of which are more frequent in the world,
SCA (Hb SS), heterozygotes (Hb SC, Hb SE, Hb SD), sickle thalassemia (Hb Sβ+ and Hb Sβ0),
Figure 13. Genograms showing the most prevalent SCD genotypes in the world and the likelihood of homozygous or
heterozygosis independent of sex when the parents have some type of hemoglobin variant that can generate SCD. The
GENOPRO® software version 2016 was used to make the genograms.
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and sickle cell trait (Hb AS) [8, 84, 104, 113, 114]. Individuals with Hb SS genotypes, heterozy-
goses and associations with thalassemia are generally symptomatic, and at each gestation,
there is a 25% chance that the child will be born with SCD from parents carrying some S gene
or other variant hemoglobin (Figure 13) [84, 104, 115]. In general, the HbAS genotype is
considered to be asymptomatic in that it hardly develops any clinical picture, but it represents
a type of hemoglobinopathy, since the recessive gene is likely to be inherited for the next
generation [115–118].
Other indicators of disease severity are bilirubin, PCV, erythropoiesis rate, leukocytes, LDH,
fetal hemoglobin, creatinine, proteinuria, reticulocytes, HSV, phenotypes, days of hospitaliza-
tion per year, severe vaso-occlusive crisis per year, number of transfusions per year, hip
disease, leg ulcer, hepatobiliary complications, neurological events, renal disorders and body
mass index [84, 119–123].
5. Treatment of SCD: general aspects
Treatment, in general, is differentiated by pathophysiological changes during life and will also
depend on the type of genotype, which is accompanied by a hematologist. The use of folic acid
supplements is included in order to contain hemolysis and to accelerate the production of red
blood cells.
Also used are: (A) antibiotics, especially in children under 5 years, since generalized infections
can lead to death within a few hours due to splenic sequestration; (B) analgesics, codeine,
morphine, and anti-inflammatories in the presence of acute or chronic pain crises; venous
hydration in the vessel occlusion; (C) transfusion or blood exchange; (D) periodic and special
immunizations; and (E) treatment of the sequelae or chronic consequences caused by the
disease [18, 124, 125].
The use of hydroxyurea medication over the years as a treatment that greatly increased the
quality of life of patients. However, not all individuals are eligible or adapted to their use
[77, 126]. Alternative treatments, transplantation, and gene therapy are welcome measures for
clinical treatment; however, some of these are still under discussion and require technical and
scientific clarification for their implementation.
Clinical and biochemical markers of disease severity should be used to predict risk, prevent com-
plications, and increase the expectation and quality of life of the population with SCD [77, 87, 127].
Often patients with SCD report the development of vaso-occlusive symptoms after emotional/
psychological stress, temperature changes, and physical exertion [95]. Therefore, patients undergo-
ing treatment and their caregivers are encouraged to practice self-care, with measures that can
prevent acute events, improve prognosis, and allowa better quality of life [128].
In general, people with SCD due to chronic hemolysis and inflammatory state have higher
energy expenditure to develop daily activities and tendency to anorexia [109, 129, 130]. Pain
crises generate a decrease in food consumption, which has a direct impact on caloric and nutrient
intake. Probably, the pain crises associated with the constant hospitalizations contribute to the
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lower food consumption that consequently compromises the nutritional status [127, 129, 130].
Thus, this population calls for nutritional monitoring for the intervention of the problems related
to food and nutrition. In general, it is important the presence of a multi-professional team,
centered in the assistance and matrix support to the hematologist doctor and the patients
assisted with SCD.
6. Conclusion
Scientific research and technical work around the world have been done to better understand
the pathophysiological and clinical aspects of SCD. It is a severe hemolytic disease that causes
great morbidity and mortality, especially in underdeveloped countries. The entire scenario
generated by HbS has implications for the health and social inclusion of patients, so the
treatment of the person with SCD needs an approach focused on the prevention of these
complications in an individualized way.
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